Reimbursement Rejection On Cost Grounds For “Highly Effective” Trodelvy In England
Country Out Of Sync With Other Project Orbis Markets On Gilead Product
In a draft decision NICE, the health technology appraisal body for England and Wales, has declined to recommend Gilead’s Trodelvy for triple negative breast cancer patients.
You may also be interested in...
Health technology assessment body NICE has reversed its previous rejections of Novartis’s Piqray and Gilead’s Trodelvy, both for treating advanced breast cancer. Meanwhile, there are calls to speed up reimbursement decisions for breast cancer drugs.
As well as now backing the reimbursement of Bavencio for urothelial cancer, the health technology assessment institute has recommended Koselugo, for neurofibromatosis type 1, and Evenity, the osteoporosis drug that will now target over 20,000 people in England and Wales. On the other hand, Piqray has for now been turned down for advanced breast cancer.
Gilead suggests that the UK could take lessons from France on rapidly making innovative new treatments available after approval.